Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPSC-EVs with Temporal Muscle Flap for Moyamoya Disease
NCT07065409Phase 1Recruiting
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Lipid-based Nanoparticles, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NouvSoma002-01 in Moyamoya disease. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 1 month, Imaging examinations at 1 month and 1 more. Started May 2025; status: recruiting.
02
Drugs
NouvSoma002-01
03
Conditions
Moyamoya disease
Beyond the preview
Go deeper on NCT07065409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07065409.